Maria Crowe - Eli Lilly President - Manufacturing Operations

LLY Stock  EUR 717.50  3.50  0.49%   

President

Ms. Maria A. Crowe is President Manufacturing Operations of the Company since 2012.
Age 55
Tenure 12 years
Phone317 276 2000
Webhttps://www.lilly.com
Crowe was senior vice president for global drug product manufacturing of the company. She was general manager of manufacturing sites in Ireland and Puerto Rico. As head of manufacturing operations, she will lead a network of 22 sites in 13 countries and also will have responsibility for Lilly global contractmanufacturing organization. She has served as senior vice president for global drug product manufacturing since August 2009. In this role, she has overseen all of Lilly drug product manufacturing, packaging, and distribution operations. In her 29year Lilly career, she has held roles in drug product and active pharmaceutical ingredient manufacturing, as well as in sourcing and procurement. Prior to her current role, she was vice president for drug product manufacturing in the Americas

Eli Lilly Management Efficiency

The company has return on total asset (ROA) of 0.11 % which means that it generated a profit of $0.11 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6267 %, meaning that it generated $0.6267 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 14.74 B in total debt with debt to equity ratio (D/E) of 648.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Eli Lilly And has a current ratio of 1.1, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly And sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Benjamin FinkApple Inc
47
Robert ReevesApple Inc
59
Amanda McMillianApple Inc
44
Michael PearlApple Inc
44
John ColglazierApple Inc
N/A
Robert GwinApple Inc
54
Mitchell IngramApple Inc
55
Daniel BrownApple Inc
42
Darrell HollekApple Inc
58
John ColglazierApple Inc
N/A
Michael PearlApple Inc
44
Robert ReevesApple Inc
59
Ernest LeyendeckerApple Inc
55
Robert DanielsApple Inc
56
Robin FielderApple Inc
37
Christopher ChampionApple Inc
48
Robert DanielsApple Inc
56
Darrell HollekApple Inc
58
Robin FielderApple Inc
37
Ernest LeyendeckerApple Inc
55
James KlecknerApple Inc
57
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 33815 people. Eli Lilly And (LLY) is traded on Frankfurt Exchange in Germany and employs 39,000 people.

Management Performance

Eli Lilly And Leadership Team

Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ellen Marram, Lead Independent Director
Kathi Seifert, Independent Director
Ralph Alvarez, Independent Director
Jamere Jackson, Independent Director
Joshua Smiley, CFO, Senior Vice President
Fionnuala Walsh, Senior Vice President - Global Quality
Juan Luciano, Director
Alonzo Weems, VP Officer
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business
Anat Ashkenazi, VP CFO
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health
John Lechleiter, Chairman of the Board and Presidentident, CEO
Karen Horn, Independent Director
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Darren Carroll, Senior Vice President - Corporate Business Development
William Kaelin, Director
Jacob Naarden, CEO VP
Barton Peterson, Senior Vice President - Corporate Affairs and Communications
Derica Rice, CFO, Executive Vice President - Global Services
Enrique Conterno, Senior Vice President and President - Lilly Diabetes
Raul Alvarez, Independent Director
Marschall Runge, Director
Michael Harrington, Senior Vice President General Counsel
David Hoover, Independent Director
Maria Crowe, President - Manufacturing Operations
Anat JD, Gen VP
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Diogo Rau, VP Officer
Donald Zakrowski, Chief Fin
Jan Lundberg, Executive Vice President - Science and Technology and Presidentident - Lilly Research Laboratories
Carolyn Bertozzi, Independent Director
Erik Fyrwald, Independent Director
Susan Mahony, Senior Vice President and President - Lilly Oncology
Jackson Tai, Director
Michael Eskew, Independent Director
Martin MIBS, VP Projects
Katherine Baicker, Independent Director
Stephen Fry, Senior Vice President - Human Resources and Diversity
Franklyn Prendergast, Independent Director

Eli Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly And. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.